Evaluation of safety and efficacy of warfarin therapy by using Time in Therapeutic Range in patients receiving warfarin in Assiut University Hospital | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Articles in Press, Accepted Manuscript, Available Online from 02 August 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2025.398184.2608 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Shimaa Sayed Khidr1; Engy Safwat Nageeb   2; Gamal A. El-Gendy3; Ahmed Shawky Ghanem 2
| ||||
| 1Cardiovascular Medicine Department, Faculty of Medicine, Assiut University, Assiut | ||||
| 2Clinical Pharmacy Department, Faculty of Pharmacy, Assiut University, Assiut | ||||
| 3Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt | ||||
| Abstract | ||||
| Warfarin, an oral anticoagulant drug, is frequently linked to under or over-coagulation, necessitating close monitoring using the International normalized ratio (INR). Time in Therapeutic Range (TTR) is the percentage of time the INR stays within the target range, but it's not commonly used in clinical practice. The study evaluated warfarin therapy's effectiveness using "Percent in Range" and "Rosendaal" methods and explored the factors influencing TTR control. This was an observational cross-sectional study conducted between May 2022 and February 2023, involved 500 patients taking warfarin therapy, for various indications. The Rosendaal method revealed 43.0% of cases had poor control (TTR< 50%), (26.2%) had good control (TTR > 70%), while the Percent-in-range method showed 33.6% of cases had poor control and 15.4% had good control. Young age and high HAS-BLED scores are significantly related to poor control with a p-value of (0.048, < 0.001), respectively. Addressing these factors could improve treatment outcomes. | ||||
| Keywords | ||||
| Anticoagulation; Atrial fibrillation; International normalized ratio | ||||
|
Statistics Article View: 31 |
||||
